Big Moving Stock chart patterns and volume.

Nasdaq: GOOG NFLX BIIB AMZN TSLA ILMN ALXN AMGN COST GMCR CELG FFIV AAPL MDVN WDC Z GILD BMRN ROST
Nyse: ACT V LNKD AGN PCP IVV SPG LMT GS FDX MMM IBM PXD CMI TWC ANTM BA PANW PX TMO
New Highs: CF ACT AGN MCK SPG PSA LMT BCR PCYC NOC HUM ANTM ULTA VRTX CELG UTX MNST UNH CNC CI

The Hot Industries

Health Care Plans 5
Biotechnology 2
Aerospace/Defense Products & Services 2

The Hot Sectors

Healthcare 11
Industrial Goods 3
Financial 2

Social Buzz

ARIA is headed higher?

ARIA Stock ChartSimilar Stocks: MRK AMGN PFE CELG BMY AMBI NVS


ARIA
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

307
Monthly

Website:

http://www.ariad.com

ARIA Ariad Pharmaceuticals Inc.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

favicon

First Week of ARIA March 20th Options Trading

23 Jan 2015, 9:43 amFirst Week of ARIA March 20th Options Trading
favicon

ARIAD's Iclusig Endorsed by EC for All Approved Indications - Analyst Blog

21 Jan 2015, 12:00 pmARIAD Pharmaceuticals, Inc. (ARIA) announced that the European Commission endorsed the CHMP's recommendation on the use of Iclusig in its approved indications.
favicon

ARIAD Reveals 2015 Strategic Objectives, Updates on Pipeline - Analyst Blog

14 Jan 2015, 4:05 pmARIAD Pharmaceuticals, Inc. (ARIA) announced its key strategic objectives for 2015 and its aim to increase R&D and expand business development activities.
favicon

Credit Suisse's 4 Healthcare Stocks To Avoid

11 Jan 2015, 11:15 amIn a recent report, analysts at Credit Suisse outlined their 2015 outlook for healthcare stocks. Here’s a breakdown of their top stocks to avoid in 2015. 1. United Therapeutics Corp (NASDAQ: UTHR ): Analysts ...
favicon

February 27th Options Now Available For ARIAD Pharmaceuticals (ARIA)

8 Jan 2015, 11:02 amFebruary 27th Options Now Available For ARIAD Pharmaceuticals (ARIA)
favicon

Is Ariad Pharmaceuticals (ARIA) Stock a Solid Choice Right Now? - Tale of the Tape

2 Jan 2015, 8:34 amIs Ariad Pharmaceuticals (ARIA) Stock a Solid Choice Right Now? - Tale of the Tape
favicon

ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog

31 Dec 2014, 12:35 pmARIAD Pharmaceuticals, Inc. (ARIA) announced that it has granted exclusive rights to privately-held pharmaceutical company Angelini Pharma to commercialize Iclusig in Central and Eastern Europe.
favicon

ARIA Widens Sales Turf, NRX Skips A Beat, NDRM Triples On Parkinson''s Study

30 Dec 2014, 9:49 pmARIA Widens Sales Turf, NRX Skips A Beat, NDRM Triples On Parkinson''s Study
favicon

ARIA Widens Sales Turf, NRX Skips A Beat, NRDM Triples On Parkinson's Study

30 Dec 2014, 9:48 pmARIA Widens Sales Turf, NRX Skips A Beat, NRDM Triples On Parkinson's Study
favicon

ARIA: Insiders vs. Shorts

29 Dec 2014, 1:26 pmThe most recent short interest data was recently released by the NASDAQ for the 12/15/2014 settlement date, and ARIAD Pharmaceuticals, Inc. (NASD: ARIA) is one of the most shorted stocks of the Russell 3000, based on 6.18 "days to cover" versus the median component at 5.32. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover ...